Editing Life: The Promise and Peril of CRISPR
In 2012, scientists described a way to edit DNA with unprecedented precision. The tool, known as CRISPR-Cas9, was adapted from a defence system that bacteria use against viruses. In simple terms, it works like a pair of molecular scissors guided by a GPS: a short piece of RNA leads an enzyme to a specific location in the DNA, where it makes a cut. The cell's own repair processes then fix the break, and scientists can use that moment to disable a gene or insert a new sequence. In 2020, Jennifer Doudna and Emmanuelle Charpentier received the Nobel Prize in Chemistry for this work.
The possibilities are remarkable. Researchers are using CRISPR to develop treatments for inherited blood disorders such as sickle cell disease, and in 2023, regulators in several countries approved the first CRISPR-based therapy for it. Scientists are also exploring crops that resist drought or disease, and studying how genes contribute to conditions ranging from cancer to blindness.
Yet the same power raises profound ethical questions. A crucial distinction is between somatic editing, which changes the cells of one patient and is not inherited, and germline editing, which alters embryos, eggs or sperm so that changes pass to future generations. In 2018, a researcher in China announced the birth of twin girls whose embryos he had edited. The announcement was widely condemned by scientists around the world, and he was later imprisoned. Critics argued that the procedure was unsafe, medically unnecessary and carried out without proper oversight or truly informed consent.
Beyond safety, there are concerns about fairness and the future of human diversity. If genetic enhancements, not just treatments, ever became possible, would they be available only to the wealthy? Who decides which traits count as a "disorder"? Many people in disability communities have warned that such decisions could reinforce the idea that some lives are less valuable than others.
Most scientific organizations currently support continued research on somatic therapies under strict regulation, while calling for great caution, or a pause, on heritable germline editing. As the technology advances, the questions it raises are not only scientific. They belong to everyone.
